GIA
HOWL icon

GHP Investment Advisors’s Werewolf Therapeutics HOWL Stock Holding History

GHP Investment Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-80
Closed -$185 – 891
2023
Q3 		$185 Hold
80
– – ﹤0.01% 921
2023
Q2 		$209 Buy
+80
New +$225 ﹤0.01% 902

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

GHP Investment Advisors's HOWL Position: Q4 2023 in Review

GHP Investment Advisors sold out of Werewolf Therapeutics (HOWL) in Q4 2023, closing a stake of 80 shares — an estimated $185 sold.

GHP Investment Advisors first reported a position in HOWL in Q2 2023 and held it in 2 quarters. The position peaked at $209 in Q2 2023. 41 funds tracked by Wall St. Rank hold HOWL as of Q4 2023.

  • GHP Investment Advisors reported no remaining Werewolf Therapeutics position as of Q4 2023 after selling out during the quarter.
  • GHP Investment Advisors sold 80 Werewolf Therapeutics shares in Q4 2023, an estimated $185.
  • GHP Investment Advisors first reported a position in Werewolf Therapeutics in Q2 2023 and held it in 2 quarters.
  • GHP Investment Advisors's Werewolf Therapeutics position peaked at $209 in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2023.

Based on GHP Investment Advisors's 13F filing for Q4 2023, filed 26 Jan 2024.